Germline mutations in BRAF are a major cause of cardio-facio-cutaneous (CFC) syndrome, which is characterized by heart defects, characteristic craniofacial dysmorphology and dermatologic abnormalities. Patients with CFC syndrome also commonly show gastrointestinal dysfunction, including feeding and swallowing difficulties and gastroesophageal reflux. We have previously found that knock-in mice expressing a Braf Q241R mutation exhibit CFC syndrome-related phenotypes, such as growth retardation, craniofacial dysmorphisms, congenital heart defects and learning deficits. However, it remains unclear whether Braf Q241R/þ mice exhibit gastrointestinal dysfunction. Here, we report that Braf Q241R/þ mice have neonatal feeding difficulties and esophageal dilation. The esophagus tissues from Braf Q241R/þ mice displayed incomplete replacement of smooth muscle with skeletal muscle and decreased contraction. Furthermore, the Braf Q241R/þ mice showed hyperkeratosis and a thickened muscle layer in the forestomach. Treatment with MEK inhibitors ameliorated the growth retardation, esophageal dilation, hyperkeratosis and thickened muscle layer in the forestomach in Braf Q241R/þ mice. The esophageal dilation with aberrant skeletal-smooth muscle boundary in Braf Q241R/þ mice were recovered after treatment with the histone H3K27 demethylase inhibitor GSK-J4. Our results provide clues to elucidate the pathogenesis and possible treatment of gastrointestinal dysfunction and failure to thrive in patients with CFC syndrome.
Introduction
The proto-oncogene BRAF is a serine/threonine protein kinase that plays major roles in the regulation of the phosphorylation and activation of MEK/ERK as RAS signal effectors. BRAF has three conserved domains: conserved region (CR) 1, CR2 and CR3. CR1 contains the RAS-binding domain and the cysteine-rich domain, which are involved in the membrane recruitment of RAF and the interaction with RAS; CR2 contains the 14-3-3 scaffolding protein binding sites; and CR3 contains the catalytic kinase domain (1) . Somatic mutations in BRAF occur at a high frequency in numerous human cancers, particularly melanoma, papillary thyroid carcinoma and colorectal cancer (2) . BRAF is ubiquitously expressed in murine organs at mid-gestation, and it is highly expressed in the fetal brain and adult cerebrum and testes (3, 4) . Braf knockout mice die between E10.5 and E12.5, owing to enlarged blood vessels, apoptotic death of differentiated endothelial cells and neuronal defects (5) .
Cardio-facio-cutaneous (CFC) syndrome is a multiple congenital anomaly disorder, characterized by heart diseases, dysmorphic facial features, failure to thrive, intellectual disability, dermatologic abnormalities, seizures and gastrointestinal dysfunction (6, 7) . In 2006, our group and another group reported that CFC is an autosomal dominant genetic disorder caused by mutations in BRAF, MAP2K1, MAP2K2 and KRAS, all of which belong to the RAS/MAPK pathway, which regulates cell differentiation, proliferation, survival, apoptosis and senescence (8) (9) (10) . The most common somatic mutation in BRAF is a substitution of the residue V600E in the CR3 domain, which accounts for 90% of BRAF mutations in cancers. In contrast, the most common mutation in CFC syndrome is the BRAF Q257R mutation in the cysteine-rich domain within the CR1. The BRAF mutations found in patients with CFC syndrome lead to the activation of the RAS/MAPK pathway as well as cancer-related BRAF mutations, such as BRAF V600E (8, 11) .
We have previously generated heterozygous knock-in mice on a C57BL/6 J genetic background (Braf Q241R/þ B6) that express the Braf Q241R mutation, which corresponds to the human BRAF Q257R mutation. These mice show embryonic and neonatal lethality resulting from craniofacial abnormalities, edema, liver necrosis and congenital heart defects, including pulmonary valve stenosis and ventricular septal defects (12) . Prenatal treatment with the MEK inhibitor PD0325901 or the histone H3K27 demethylase inhibitor GSK-J4 rescues the embryonic and neonatal lethality in Braf Q241R/þ B6 mice. Furthermore, in a recent study, we found that the embryonic and neonatal lethality improved when the surviving Braf Q241R/þ B6 mice treated with PD0325901 were crossed with closed-colony ICR/CD-1 mice. Approximately, 50% of the Braf Q241R/þ mice on an ICR background (Braf
) died within 4 weeks after exhibiting failure to thrive. The surviving adult Braf Q241R/þ mice showed typical CFC syndrome features, including cardiomegaly, pulmonary valve stenosis, atrial septal defects, craniofacial dysmorphism, mild growth retardation, learning deficits, hair abnormality, a hunched appearance and long and/or dystrophic nails (13) . Furthermore, the Braf Q241R/þ mice displayed extra digits and ovarian cysts, which have not been found in CFC syndrome. However, the primary cause of death in the Braf Q241R/þ neonatal mice with failure to thrive remains unknown. Feeding problems in patients with CFC syndrome are common causes of failure to thrive and poor growth in the neonatal period. Feeding problems include gastroesophageal reflux, sucking/swallowing difficulties, aspiration and oral aversion (6, 14) . Therefore, assisted feeding with a nasogastric or gastrostomy tube is commonly used in 40 to 50% of CFC individuals (6) . The gastrointestinal dysfunction, including constipation and intestinal malrotation, also occurs in individuals with CFC syndrome. In the present study, we observed that Braf Q241R/þ mice showed esophageal dilation and decreased motility due to an aberrant skeletal-smooth muscle boundary and gastrointestinal dysfunction. Furthermore, a pharmacological intervention with MEK inhibitors (PD0325901, MEK162, and AZD6244) or GSK-J4 reversed the digestive system abnormalities in the Braf Q241R/þ mice.
Results
Braf Q241R/þ mice develop esophageal dilation, hyperkeratosis, a thickened muscle layer and hyperproliferation of the muscularis mucosae in the forestomach
We have previously reported that approximately half of the Braf Q241R/þ neonatal mice on an ICR background exhibit growth retardation and feeding problems, and die within 4 weeks. Thereafter, 23% (6 of 26) of the surviving Braf Q241R/þ mice die in the adult stage from severe growth retardation and a decreased body weight (50% that of control mice) within 1 year (13). We therefore examined whether the feeding problems and severe growth retardation might be caused by esophageal and gastrointestinal abnormalities in the Braf Q241R/þ mice. The stomachs of Braf Q241R/þ mice with severe growth retardation were smaller than those of the Braf þ/þ mice (Fig. 1A) . The Braf Q241R/þ mice showed megaesophagus with digested food, malrotation of the stomach, dilation of the jejunum and cecum, and constipation with fecal impaction (Fig. 1A, Supplementary Material, Fig. S1A-D) . Histological and immunohistochemical examinations revealed a cornified epithelium, an increased thickness of the muscle layer and hyperproliferation of the muscularis mucosae in the forestomach in the Braf Q241R/þ mice (Fig. 1B) ; however, the mucosa in the glandular stomach was intact. In the Braf Q241R/þ mice, the lower esophageal sphincter (LES) and proximal esophagus of the LES showed a cornified epithelium and decreased thickness of the muscle layer (Fig. 1C) . Patients with achalasia and megaesophagus develop fibrosis of the LES during the later stages of the disease (15) . Sirius red staining indicated no differences in fibrosis of the LES between the Braf þ/þ and Braf Q241R/þ mice (data not shown).
BRAF is expressed at high levels in neuronal tissues and the testis in the adult stage (3, 4) . However, it is not known whether Braf is expressed in the esophagus and stomach in the embryonic and adult stages. A western blot analysis detected expression of the BRAF protein at high levels in the brain, lung, esophagus, stomach and testis tissues, and low levels were detected in the heart tissues of adult ICR mice (Fig. 1D) . In situ hybridization of tissues from the ICR mice at E18.5 revealed signals that were widely distributed in the skin, nasal cavity, tooth germ, ganglion, pancreas, bladder, heart and neuronal tissues, including the cerebral cortex, hippocampus, striatum, thalamus, midbrain and spinal cord (Supplementary Material, Fig. S2 ). The expression of Braf was also detected both in the muscle layer and epithelium of the esophagus and stomach ( Fig. 1E and F) . In addition, immunohistochemistry staining confirmed that BRAF was expressed in the epithelium in the esophagus and forestomach of adult ICR mice (Fig. 1G) . These results suggested that Braf is expressed in the esophagus and stomach at the embryonic and adult stages of ICR mice.
We investigated whether Braf Q241R/þ mice without severe growth retardation exhibit megaesophagus, malrotation of the stomach, dilation of the jejunum and cecum, constipation with fecal impaction, and the hyperkeratotic phenotype in the LES and forestomach. The esophageal width was significantly larger in the Braf Q241R/þ mice than in the Braf þ/þ mice (Fig. 1H, Supplementary Material, Table S1 ). In addition, the esophageal width in the Braf Q241R/þ mice increased with age. In particular, the Braf Q241R/þ mice with severe growth retardation had a prominent esophagus width (4.41 6 0.36). The esophagus length in the Braf Q241R/þ mice was longer than that in the Braf þ/þ mice, and the esophagus length to body length ratio was significantly higher (Supplementary Material, Table S1 ). Hyperkeratosis, an increased thickness of the muscle layer and hyperproliferation of the muscularis mucosae in the forestomach were observed in the Braf Q241R/þ mice (Fig. 1I) Table S2 ). The Braf Q241R/þ mice also had aerophagy (data not shown). The gross observations indicated dilated esophagus in the Braf Q241R/þ mice at P7 (Fig. 2B) .
Furthermore, the morphometric evaluation revealed that the esophagus width in the Braf Q241R/þ mice was significantly greater than that in the Braf þ/þ mice at P0, P7-P8 and P14-P16 (Fig. 2C , Table S2 ). Braf Q241R/þ mice with a severe growth retardation and esophageal dilation at P7 displayed a thickened stratum corneum in the skin (Supplementary Material, Fig. S3 ). On the basis of the esophageal histology at P0-P7, the esophageal structures were similar between the Braf þ/þ and Braf Q241R/þ mice. However, a detached cornified layer and food particles were observed in the esophagus in Braf Q241R/þ mice at P10 and P14, and P20, respectively (Fig. 2D ). At P3, the Braf Q241R/þ mice developed a marked proliferation of the stratified squamous epithelium and muscularis mucosae in the forestomach (Fig. 2E , Supplementary Material, Fig. S4A ). All Braf Q241R/þ mice at P14 had a thickened muscle layer, although the increased thickness of the muscle layer was observed in 3 of 6 Braf Q241R/þ mice at P10 (Fig. 2E, Supplementary Material, Fig. S4A ). To examine whether the hyperkeratosis of the forestomach observed in the Braf Q241R/þ mice might be caused by changes in cell proliferation, we performed immunostaining using Ki67 to assess cell proliferation. Ki67-positive-stained epithelial cells in the forestomach increased in Braf Q241R/þ mice at P7 (Fig. 2F ).
The esophagus in the Braf Q241R/þ mice has an aberrant skeletal-smooth muscle boundary
The mammalian esophageal walls initially develop as smooth muscle. Subsequently, smooth muscle is replaced by skeletal muscle in a proximal-to-distal manner (16, 17) . In human adults, the upper third of the esophagus wall is composed of skeletal muscle cells, the middle third is composed of a mixture of smooth and skeletal muscle cells, and the lower third is composed of only smooth muscle cells. In contrast, the murine esophagus is composed of skeletal muscle cells, except for the LES, which is composed of smooth muscle cells (18) . Several studies using knockout mice have suggested an association between a megaesophagus with delayed myogenic differentiation and dysplasia in the esophagus (17, (19) (20) (21) (22) . To examine the myogenic differentiation in the esophagus in Braf Q241R/þ mice, we performed immunostaining with markers of smooth muscle (a-smooth muscle actin; a-SMA) and skeletal muscle (sarcomeric actin; SA). All 10-week-old Braf
mice showed a-SMA expression in the LES and SA expression in the esophagus, whereas 6 of 8 Braf Q241R/þ mice had an aberrant skeletal-smooth muscle boundary (Fig. 3A) . The Braf Q241R/þ mice exhibiting megaesophagus also showed a-SMA expression from the proximal to distal LES (data not shown). The smooth muscle cells in mouse esophagus are replaced by skeletal muscle cells at 14 days after birth (16, 23) . At P10, the skeletal-smooth muscle boundary in the LES was not clearly observed in either Braf þ/þ or Braf Q241R/þ mice ( Fig. 3B ). At P14 and P20, the skeletal-smooth muscle boundary in the LES was clearly observed in the Braf þ/þ mice, whereas the Braf Q241R/þ mice displayed delayed skeletal myogenesis. The Ki67 immunostaining revealed that Ki67-positive cells were observed in the transition zone, which is where smooth muscle cells and skeletal muscle cells are mixed, in both the Braf þ/þ mice at P10 and Braf Q241R/þ mice at P14; however, Ki67-positive cells in the esophagus in the Braf Q241R/þ mice were detected in the distal region of the LES ( Fig. 3B and C) . The decrease in Ki67-positive cells in the Braf þ/þ mice at P14 and P20 and the Braf Q241R/þ mice at P20
resulted in the termination of the myogenic differentiation ( Fig. 3C-E ). At P0, the pharyngo esophagus was devoid of smooth muscle in Braf þ/þ mice, whereas a-SMA expression was observed in the Braf Q241R/þ mice (Supplementary Material, Fig. S5A ).
Moreover, a-SMA expression was found in the esophagus on the thorax in Braf Q241R/þ mice at P7, P10 and P14 but not in Braf 
Braf

Q241R/þ mice display decreased esophageal motility
Achalasia is characterized by an esophageal motility dysfunction with impaired relaxation of the LES and decreased peristalsis due to impaired inhibitory nitrergic neurons in the esophageal myenteric (Auerbach's) plexus (24) . To investigate whether Braf Q241R/þ mice could develop achalasia, we performed immunostaining of the LES in Braf þ/þ and Braf Q241R/þ mice by using antibodies against protein gene product 9.5 (PGP9.5; neuronal marker). There were no differences in the numbers of PGP9.5-positive cells in the Braf þ/þ and Braf Q241R/þ mice [51.25 6 mice. The expression of the inhibitory neuron markers Nos1, acetylcholinesterase (Ache1), vasoactive intestinal polypeptide (Vip1), neurotrophic factors, Gdnf1 and Ngf were comparable in the Braf þ/þ and Braf Q241R/þ mice (Fig. 4B) . Western blotting analysis revealed that the levels of phosphorylated ERK protein were significantly lower in the Braf Q241R/þ mice than in the Braf þ/þ mice [1.00 6
. Consistent with the decreased phosphorylated ERK levels, the protein levels of kinase suppressor of RAS (KSR-1) were significantly higher in the Braf Q241R/þ mice [1.00 6 (Fig. 4C) , thus suggesting that a negative feedback mechanism exists that normalizes constitutive ERK activation in the esophagus in Braf Q241R/þ mice. There were no differences in the neuron markers, including nNOS, Tublinb3 and c-kit, cell signaling factors, phosphorylated p38, AKT (Ser473) and AKT (Thr308) in the Braf þ/þ and Braf Q241R/þ mice. Because the Braf Q241R/þ mice developed esophageal dilation without a loss of neurons, as a result of impaired myogenic differentiation, we evaluated the esophageal motility function in the Braf Q241R/þ mice at the age of 14-18 weeks. By exploring the nerve-independent and nerve-dependent contractions induced by a high concentration of KCl and carbachol (CCh), respectively, the contraction force of the LES was similar in the Braf þ/þ mice and Braf Q241R/þ mice (Supplementary Material, Fig. S6B ). In contrast, the esophageal tissues from the Braf Q241R/þ mice showed significantly decreased contractile responses to CCh and slightly decreased responses to KCl (Fig. 4D-F) .
Cell adhesion-and epithelium development-associated gene expression is increased in the forestomach in Braf Q241R/þ mice
We then examined the neuronal cells and the motility function in the forestomach in Braf Q241R/þ mice. In agreement with the increased thickness of the muscle layer in the forestomach in the Braf Q241R/þ mice at P10 and P14, the Braf Q241R/þ mice exhibited a marked increase in the numbers of S100 [At P10: 803.1 6 854.1 (Braf (Fig. 5B) . Although the neural cells increased in the forestomach in the Braf Q241R/þ mice, the analysis of the contractile response in the forestomach to CCh revealed no differences between the Braf þ/þ and Braf Q241R/þ mice (data not shown). To determine whether the neuronal gene expression and cell signaling pathways, including ERK, p38 and Akt, were altered in the Braf Q241R/þ mice, western blotting was performed using cell extracts from the forestomach. The protein levels of PGP9.5, nNOS, Tublinb3, c-Kit, phosphorylated ERK, p38 and To investigate the mechanism of the hyperkeratosis, thickened muscle layer and hyperproliferation of the muscularis mucosae in the forestomach of the Braf Q241R/þ mice, a microarray analysis was performed using forestomach tissues from the Braf þ/þ and Braf Q241R/þ mice at P3. Using a 1.5-fold expression difference as the cut-off, we found 115 up-regulated genes and 38 down-regulated genes. The up-regulated genes were analysed by using the database for annotation, visualization and integrated discovery (DAVID), which is a functional annotation tool. The top three terms in biological process were cell adhesion, biological adhesion and epithelium development, and the top three terms in cellular components were desmosome, extracellular region and integral to plasma membrane (Supplementary Material, Table S3 ). RT-PCR revealed that the mRNA levels of Cdh13, Cgref1 and Gpnmb, which were selected as genes categorized in cell adhesion and biological adhesion of biological process, were significantly increased in Braf Q241R/þ mice compared with Braf þ/þ mice (Fig. 5C ). In the associated genes in epithelium development, the expression of Etv4, Krt14 (basal cytokeratin) and Sprr1b (a squamous differentiation marker) was also significantly higher in Braf Q241R/þ mice than in (Fig. 5D) . Consistently with the hyperkeratosis The data are shown as the mean
phenotype and the increased Krt14 expression in the Braf Q241R/þ mice, the Krt5 (paired with Krt14) mRNA levels, but not the KRT5 protein levels, were significantly higher in the Braf Q241R/þ mice than in the Braf þ/þ mice (Fig. 5E, Supplementary Material,   Fig. S7A ). The expression of suprabasal cytokeratin, Krt13, was also significantly higher in the Braf Q241R/þ mice than in the Braf þ/þ mice. In addition, the histological analysis and immunohistochemistry using the anti-keratin 5 antibody revealed that the forestomach in the Braf Q241R/þ mice had a disorganized basal layer and increased keratin 5 expression ( Fig. 5F and G).
MEK inhibitors and GSK-J4 rescued the gastrointestinal phenotypes in the Braf Q241R/þ mice
We have previously reported that treatment with the MEK inhibitor PD0325901, or the histone demethylase inhibitors GSK-J4 or NCDM-32 b, prevents the embryonic and postnatal lethality in Braf Q241R/þ mice on a C57BL/6 J background (12) . These results suggest that the inhibition of ERK activation and alteration of histone modification may be useful for effective treatment of patients with CFC syndrome. We therefore investigated the effects of MEK inhibitors (i.e., PD0325901, MEK162, AZD-6244 and trametinib), histone demethylase inhibitors (i.e., GSK-J4 and NCDM-32 b) and other inhibitors (i.e., SAHA, rapamycin and FK506) on the gastrointestinal abnormalities in Braf Q241R/þ mice. A 13-day treatment with PD0325901, but not GSK-J4, in nursing female mice resulted in an increase in body weight and body length in 14-day-old Braf Q241R/þ mice. The body weight and length of the MEK162-treated Braf Q241R/þ mice were significantly greater than those of the DMSO-treated Braf Q241R/þ mice and were comparable to those of the MEK162-treated Braf þ/þ mice (Fig. 6A, Supplementary Material, Table S4 ). Because the trametinib, rapamycin and FK506 Table S4 ).
The gross observations showed that the stomach size and milk content in the MEK162-treated Braf Q241R/þ mice were comparable with those in the MEK162-treated Braf þ/þ mice (data not shown).
The myogenic differentiation in the esophagus in 3 of 5 GSK-J4-treated Braf Q241R/þ mice was similar to that in the DMSO-treated (Fig. 6B) . Furthermore, the thickened muscle layer in the forestomach was improved in 10 of 14 PD0325901-treated Braf Q241R/þ mice, all MEK162-treated Braf Q241R/þ mice and 6 of 8 AZD6244-treated Braf Q241R/þ mice (Fig. 6C ). Hyperkeratosis and hyperproliferation of the muscularis mucosae in the forestomach were not observed in 7 of 14 PD0325901-treated Braf Q241R/þ mice and 6 of 8 MEK162-treated Braf Q241R/þ mice (Fig. 6C) . These results indicated that the MEK inhibitors, including PD0325901, MEK162 and AZD6244, or the histone H3K27 demethylase inhibitor GSK-J4, partly improve growth retardation and the esophageal and gastric phenotypes in Braf Q241R/þ mice.
Discussion
Individuals with RASopathies, such as CFC syndrome, Costello syndrome and Noonan syndrome, have gastrointestinal abnormalities, including feeding and swallowing difficulties, in the neonatal period (6, (25) (26) (27) . Furthermore, nasogastric or gastrostomy tube feedings are required in patients with CFC syndrome and Costello syndrome (6) . A patient with neurofibromatosis type 1 has been reported to have an achalasia-like disorder of the esophagus (28) . Thus, the feeding problem is common in individuals with RASopathies. However, the feeding problems, esophageal dilations and gastrointestinal dysfunctions have not been reported in the following mouse models of RASopathies: knock-in mouse model expressing Braf L597V or V600E mutation (CFC syndrome model), Hras mutation (Costello model) or Ptpn11, Raf1 or Kras mutations (Noonan syndrome model) (29) (30) (31) (32) (33) (34) . These mutations all lead to the activation of the RAS/MAPK pathway. In this study, we provide the evidence that knock-in mice expressing a gain-of-function Braf Q241R mutation show esophageal dilation, decreased esophageal motility and impaired myogenic differentiation. Notably, the Braf Q241R/þ mice on a mixed BALB/c x C57BL/6 background showed severe growth retardation and esophageal dilation with high penetrance, as compared with Braf Q241R/þ mice on an ICR background (Supplementary Material, Table S5 ), thus suggesting that these phenotypes may be genetic background-independent and associated with the Braf Q241R mutation. The Braf Q241R/þ mice also displayed hyperkeratosis, a thickened muscle layer and hyperproliferation of the muscularis mucosae in the forestomach. Furthermore, we found that treatment with the MEK inhibitors PD0325901, MEK162 and AZD6244, or a histone H3K27 demethylase inhibitor GSK-J4, partly improved the growth retardation, esophageal dilation and gastrointestinal dysfunction observed in Braf Q241R/þ mice. Thus, mice expressing the Braf Q241R mutation provide a useful model for clarifying the pathogenesis of esophageal dilation and gastrointestinal dysfunction and testing treatments for RASopathies. A dysregulation in myogenic differentiation in the esophageal wall has been associated with esophageal dilation and esophageal dysmotility. Protein kinase C alpha (PKCa), frizzled 4 and paired box protein (Pax) 7 knockout mice have been reported to develop megaesophagus with an aberrant skeletalsmooth muscle boundary (19, 21, 22) . Mice lacking a multifunctional cell surface receptor Cdo and collagen 19a1 have also been shown to have impaired myogenic differentiation in the esophagus, thus resulting in the development of megaesophagus and an abnormal esophageal motility (17, 20) . Our study demonstrated that Braf Q241R/þ mice show an esophageal dilation and a decreased esophageal contractile response to CCh after impaired myogenic differentiation. The RAS/MAPK pathway plays a crucial role in the myogenic differentiation of smooth muscle to skeletal muscle (35) . The overexpression of Raf1 or MEK1 negatively regulates myogenic differentiation in 10T1/2 cells, thus inhibiting skeletal muscle cell differentiation through a myocyte enhancer factor 2 or MyoD dependent mechanism (36, 37) . DA-Raf1, a splicing variant of Araf and a dominant negative antagonist of the RAS/MAPK pathway, has also been shown to act as a positive regulator of skeletal muscle cell differentiation (38) . In this study, our data indicated that treatment with the MEK inhibitors PD0325901, MEK162, AZD-6244 and trametinib had no effect on the myogenic differentiation in Braf Q241R/þ mice. In contrast, mice treated with the histone H3K27 demethylase inhibitor GSK-J4 showed recovery from the delayed and impaired myogenic differentiation. An increased expression of a histone H3K27 methylase, Ezh2, has been reported to inhibit skeletal muscle differentiation through an SRF-and MyoDdependent mechanism (39) . These data suggest that the modulation of histone modifications may be important for the myogenic differentiation in the esophagus wall. Dysregulation of the RAS/MAPK pathway is associated with esophageal dilation or achalasia in mice. Old mice lacking the Ras association domain family 1 isoform A (Rassf1a) have been found to have megaesophagus with a loss of neural cells (40) . Sprouty 2 is a negative regulator of the RAS/MAPK signaling pathway, and Sprouty 2 knockout mice have been reported to show neuronal hyperplasia and achalasia due to ERK activation (41) . Furthermore, lsc is the murine homologue of human p115 RhoGEF, and Isc-null mice have been found to exhibit progressive dilation and impaired peristalsis in the esophagus (42) . Remarkably, all these models have common defects in neuronal development. In contrast, the Braf Q241R/þ mice had esophageal dilation and decreased esophageal motility without any abnormalities in neuronal development. Thus, our mouse models provide a different tool to investigate the effects of the RAS/ MAPK pathway on esophageal development and motility. The Braf Q241R/þ knock-in mouse exhibited a cornified epithelium and a thickened muscle layer in the forestomach in which Braf expression was observed. Microarray and quantitative realtime PCR analysis revealed an increased expression of Cdh13, Cgref1 and Gpnmb, genes associated with cell adhesion. In agreement with the cornified epithelium in the forestomach, we also detected an increase in genes associated with cell proliferation (Etv4), epithelium development and barrier function in stratified squamous epithelial (Sprr1b), and basal layer keratin formation in the cornified epithelium (Krt5 and Krt14), suggesting the effects of the Braf Q241R mutation and/or excess epithelial cells in the forestomach. The activation of the RAS/MAPK pathway is associated with the proliferation of stratified squamous epithelial (43, 44) . Conditional Raf1 transgenic mice with a keratin 14 promoter have been shown to develop epidermal hyperplasia and hyperkeratosis in the skin (45) . Notably, PD0325901, MEK162 and AZD6244 treatments ameliorated the cornified epithelium and thickened muscle layer in the forestomach, thus suggesting that these phenotypes in Braf Q241R/þ mice are caused by activation of the MEK/ERK pathway. It remains unknown why phosphorylated ERK expression was not changed in the esophagus and forestomach tissues from the Braf Q241R/þ mice, although the Braf Q241R/þ mice had esophageal dilation and gastrointestinal dysfunction. We hypothesized that the pERK expression depends on BRAF protein level. Thus, we investigated the protein levels of pERK in several tissues, including brain, lung, kidney, esophagus and forestomach, of the Braf þ/þ and Braf Q241R/þ mice at P7 after treatment with DMSO or MEK162. Consistent with the higher BRAF expression (Fig. 1D) , the protein levels of pERK were higher in brain and lung in the Braf Q241R/þ mice than those in the Braf It is possible that cell-specific activation of pERK could be important for the phenotype, which was not detected in western blotting using whole tissue lysates. Alternatively, subtle decrease of pERK with MEK inhibitor, which might not be detected in western blotting, could be effective to improve the phenotypes. The third possibility is that negative/positive feedback could regulate the ERK phosphorylation so that the level of pERK keeps constant in affected tissues. Here, we report that Braf Q241R/þ mice display esophageal dilation and dysmotility and gastrointestinal dysfunction. Our recent study has shown that treatment with MEK inhibitors and/ or histone demethylase inhibitors leads to the amelioration of several phenotypes in Braf Q241R/þ mice on a C57BL/6 J background, including the hypertrophy of the cardiac valves, edema, mandibular hypoplasia and liver necrosis (12) . In addition, in the present study, we found that treatment with MEK inhibitors or a histone H3K27 demethylase inhibitor partly rescued the growth retardation, esophageal dilation and gastrointestinal abnormalities in Braf Q241R/þ mice. Our data suggested that treatment with MEK inhibitors and histone H3K27 demethylase inhibitors may be useful for the treatment of RASopathies with digestive system abnormalities.
Materials and Methods
Mice
Heterozygous knock-in mice on an ICR background expressing Q241R mutation, Braf Q241R ICR, have been previously reported (12, 13 
In situ hybridization
Mouse embryos at E18.5 were fixed with G-fix (Genostaff, Tokyo, Japan) at room temperature and decalcified with G-Chelate Mild (Genostaff). The decalcified embryos were then embedded in paraffin on CT-Pro20 (Genostaff) using G-Nox (Genostaff) and sectioned at 8 lm. To generate digoxigenin-labeled anti-sense and sense RNA probes, a 908 bp DNA fragment of mouse Braf cDNA (nucleotide position 2530-3437) was prepared from mouse 1 st Strand cDNA (Genostaff). The digoxigenin-labeled RNA probes were synthesized with in vitro transcription using DIG RNA Labeling Mix (Roche Diagnostics, Mannheim, Germany). Hybridization was carried out using an ISH Reagent Kit (Genostaff). The tissue sections were deparaffinized with G-Nox and rehydrated using an ethanol series and PBS. The sections were fixed with 10% formalin in PBS and treated with 4 lg/ml of Proteinase K (Wako Pure Chemicals, Osaka, Japan) in PBS for 10 min at 37 C. The sections were then re-fixed with 10% formalin in PBS for 10 min at room temperature and placed in 0.2 N HCl for 10 min at room temperature. Hybridization was performed with RNA probes at concentrations of 300 ng/ml in G-Hybo (Genostaff) for 16 h at 60 C. Staining was performed with an NBT/BCIP solution (Sigma-Aldrich) overnight. Sections were counterstained with Kernechtrot stain solution (Muto Pure Chemicals, Tokyo, Japan) and mounted with G-Mount (Genostaff).
Histology and immunohistochemistry
The tissues were fixed in 10% neutral buffered formalin and embedded in paraffin. Embedded tissues were sectioned at 3 lm and stained with hematoxylin and eosin. For the immunohistochemistry, the tissue sections were deparaffinized with xylene and rehydrated using an ethanol series and PBS. Immunohistochemistry was performed with the Histofine simple stain kit (Nichirei Bio Sciences, Tokyo, Japan) and the antibodies to the following proteins (with catalog numbers in parentheses): BRAF (9433) from Cell Signaling; a-SMA (M0851) and SA (M0874) from DAKO; PGP9.5 (AB1761-I) from Millipore; Ki67 (418071) from Nichirei Bio Sciences; and Keratin 5 (905501) from BioLegend. The signals were visualized by using a DAB Substrate Kit (Nichirei Bio Sciences). The nuclei were stained with hematoxylin.
Quantitative reverse transcription-PCR and microarray analysis
Total RNA from the esophagus or forestomach was extracted using TRIzol reagent (Invitrogen, Carlsland, CA) and purified with an RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA was reverse transcribed into cDNA using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). The PCR reactions were performed using FastStart Universal Probe Master (ROX) (Applied Biosystems) with StepOnePlus (Applied Biosystems). The amplification primers and hydrolysis probes were designed using Universal ProbeLibrary Assay Design Center (https://qpcr.probefinder.com/roche3.html).
The gene expression analyses of the forestomach tissues were performed with SurePrint G3 Mouse GE 8x60K v2 Microarrays (Agilent Technologies, Santa Clara, CA, USA) with a Low Input Quick Amp Labeling Kit One-Color (Agilent Technologies), a Gene Expression Hybridization Kit (Agilent Technologies) and a Gene Expression Wash Pack (Agilent Technologies) according to the manufacturer's protocol. The data were analysed with Agilent Feature Extraction Software, 11.5.1.1.
Measurement of esophageal contraction
Esophageal strips were isolated under a microscope after the mice were anesthetized with isoflurane, and were placed in Krebs solution (118.4 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 25 mM NaHCO 3 and 11.7 mM glucose). The esophageal strips were cut into 5 mm sections and mounted vertically in a Magnus apparatus (Panlab, Barcelona, Spain) filled with Krebs solution at 37 C and continuously bubbled. Responses to the esophageal contraction were measured under 200 lM CCh or 60 mM KCl conditions. The esophageal contraction was recorded with an isometric force transducer 
